Tag: United States

CDP to become two separate organisations – CDP, a commercial entity backed by Permira, and CDP Foundation, a non-profit, charitable organisation focused on pioneering...

- Annual Event to Be Broadcast Nationwide on NBC -TOKYO, June 11, 2026 /PRNewswire/ -- NIPPON EXPRESS HOLDINGS, INC. will serve as the presenting...

Now among the fastest-scaling monopolar RF devices worldwide, XERF™ has more than tripled its pace of adoption in recent months with Asia-Pacific and North...

From living longer to living free, people across Asia prioritize health and financial self-sufficiency to pursue independence and avoid burdening loved onesHONG KONG, June...

From living longer to living free, people across Asia prioritize health and financial self-sufficiency to pursue independence and avoid burdening loved onesHONG KONG, June...

HAMBURG, Germany, June 11, 2026 /PRNewswire/ -- AIC Inc., a leading provider of enterprise storage and server solutions, will showcase its latest AI storage...

DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,142,857 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.

A $2.7 trillion deposit. A company worth less than $1 billion. And a government that is already moving.

A $2.7 trillion deposit. A company worth less than $1 billion. And a government that is already moving.

In the news release, The Galien Foundation Announces 2026 Prix Galien UK Award Candidates for "Best Biotechnology Product," "Best Digital Health Solution," "Best Medical...